l*****7
发帖数: 2844 | 1 http://cen.acs.org/articles/90/i43/AstraZeneca-Teams-Two-Major-
AstraZeneca Teams Up With Two Major Research Contractors
By Jean-François Tremblay
Department: Business
Keywords: CRO, R&D outsourcing, layoffs, China, dmpk, in vivo
The British drugmaker AstraZeneca has established two research outsourcing
agreements as part of the restructuring of its R&D organization.
In Beijing, the Chinese pharmaceutical R&D contractor Pharmaron will set up
a dedicated research center for AstraZeneca that can accommodate “several
hundred” scientists, according to Pharmaron. Under a multiyear agreement,
the facility will provide AstraZeneca discovery services in chemistry, drug
metabolism and pharmacokinetics, and efficacy screening. It will be located
within a campus where Pharmaron already operates an R&D center for Merck
Serono.
AstraZeneca also selected Charles River Laboratories, with headquarters in
Wilmington, Mass., as its preferred partner for regulated safety assessment
and development drug metabolism and pharmacokinetics. The firms say the deal
will increase Charles River’s annual sales, which were $1.1 billion last
year, by about 1%.
AstraZeneca is in the midst of a major restructuring of its R&D organization
. Early this year, it announced that it will lay off 2,200 researchers. At
the same time, the company is increasing its presence in emerging markets.
In China, for example, it is investing $200 million to build a plant for
intravenous and solid medicines in Taizhou, Zhejiang province.
The two partnerships are a part of “our plans to evolve our R&D operating
model—creating a leaner, simpler, more flexible organization with increased
efficiencies,” AstraZeneca spokeswoman Laura Woodin tells C&EN.
Chemical & Engineering NewsISSN 0009-2347Copyright © 2012 American
Chemical Society |
|
